Report #2825408

Received Feb 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Not recovered
Vaccinated: Mar 4, 2024
Onset: Apr 2, 2024
Days to onset: 29
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (NO BRAND NAME)	UNKNOWN MANUFACTURER	1	5RK5T	—

Symptoms (1)

Eczema

Symptom narrative

Eczema Rash; This non-serious case was reported by a consumer and described the occurrence of eczematous rash in a 51-year-old female patient who received Herpes zoster (Shingles vaccine) (batch number 5RK5T, expiry date 16-APR-2026) for prophylaxis. On 04-MAR-2024, the patient received the 1st dose of Shingles vaccine. On 02-APR-2024, 29 days after receiving Shingles vaccine, the patient experienced eczematous rash (Verbatim: Eczema Rash). The outcome of the eczematous rash was not resolved. It was unknown if the reporter considered the eczematous rash to be related to Shingles vaccine. It was unknown if the company considered the eczematous rash to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 15-JAN-2025 Patient was the reporter. Concomitant medication included multiple daily medications for multiple purpose. The symptoms were treated.